- A Unique Approach to Design Potent and Selective Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP) Inhibitors
-
The epigenetic regulator CBP/P300 presents a novel therapeutic target for oncology. Previously, we disclosed the development of potent and selective CBP bromodomain inhibitors by first identifying pharmacophores that bind the KAc region and then building into the LPF shelf. Herein, we report the "hybridization" of a variety of KAc-binding fragments with a tetrahydroquinoline scaffold that makes optimal interactions with the LPF shelf, imparting enhanced potency and selectivity to the hybridized ligand. To demonstrate the utility of our hybridization approach, two analogues containing unique Asn binders and the optimized tetrahydroquinoline moiety were rapidly optimized to yield single-digit nanomolar inhibitors of CBP with exquisite selectivity over BRD4(1) and the broader bromodomain family.
- Bronner, Sarah M.,Murray, Jeremy,Romero, F. Anthony,Lai, Kwong Wah,Tsui, Vickie,Cyr, Patrick,Beresini, Maureen H.,De Leon Boenig, Gladys,Chen, Zhongguo,Choo, Edna F.,Clark, Kevin R.,Crawford, Terry D.,Jayaram, Hariharan,Kaufman, Susan,Li, Ruina,Li, Yingjie,Liao, Jiangpeng,Liang, Xiaorong,Liu, Wenfeng,Ly, Justin,Maher, Jonathan,Wai, John,Wang, Fei,Zheng, Aijun,Zhu, Xiaoyu,Magnuson, Steven
-
-
Read Online
- PIPERIDIN-1- YL-N-PYRYDI NE-3-YL-2-OXOACET AM IDE DERIVATIVES USEFUL FOR THE TREATMENT OF MTAP-DEFICIENT AND/OR MT A-ACCUMULATING CANCERS
-
Compounds are provided according to Formula (I) and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein R1, R2, R3, R4, R6, R7, R8 and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.
- -
-
Paragraph 1175
(2022/02/09)
-
- THERAPEUTIC COMPOUNDS AND USES THEREOF
-
The present invention relates to compounds of formula (I) and formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R5-R6 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II), or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.
- -
-
Page/Page column 83; 84
(2017/12/29)
-
- COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS
-
Described herein are compounds and compositions for treating drug resistant and persistent tuberculosis. Also described herein is a method of screening for identifiying biofilm formation inhibitors.
- -
-
Paragraph 00285
(2014/12/12)
-
- New access to 5-substituted 1,3-benzothiazol-2(3 H)-ones and their N -methyl analogues by a palladium coupling reaction
-
5-Substituted 1,3-benzothiazol-2(3H)-ones and their N-methyl analogues were readily prepared from the corresponding 5-bromo-1,3-benzothiazol-2(3H)-ones by means of Stille and Suzuki reactions. The compounds were substituted at the C-5 position with vinyl,
- Pirat, Celine,Ultre, Vincent,Lebegue, Nicolas,Berthelot, Pascal,Yous, Sad,Carato, Pascal
-
experimental part
p. 480 - 484
(2011/04/22)
-
